ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för lasofoxifene. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

16 träffar

Bibliografisk träff 2015-09-30

Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis.

Andersson A, Bernardi AI, Stubelius A, Nurkkala-Karlsson M, Ohlsson C, Carlsten H, Islander U.

Rheumatology (Oxford) · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/rheumatology/kev355

Bibliografisk träff 2013-11-23

CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene.

Kumar P, Song ZH.

Biochem Biophys Res Commun · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bbrc.2013.11.071

Bibliografisk träff 2010-11-10

Lasofoxifene in osteoporosis and its place in therapy.

Swan VJ, Hamilton CJ, Jamal SA.

Adv Ther · review; journal article · DOI 10.1007/s12325-010-0081-y

Bibliografisk träff 2010-07-01

Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". N Engl J Med 2010;362:686-96.

Reginster JY.

Expert Opin Pharmacother · comment; journal article · DOI 10.1517/14656561003785755

Bibliografisk träff 2010-06-01

Lasofoxifene for postmenopausal women with osteoporosis.

Katzeff BS.

N Engl J Med · letter; comment · DOI 10.1056/nejmc1003454

Bibliografisk träff 2010-06-01

Lasofoxifene for postmenopausal women with osteoporosis.

Silva-Fernández L, Andreu JL.

N Engl J Med · letter; comment · DOI 10.1056/nejmx100109

Bibliografisk träff 2010-02-01

Lasofoxifene in postmenopausal women with osteoporosis.

Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R, PEARL Study Investigators.

N Engl J Med · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa0808692

Bibliografisk träff 2009-11-02

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

Lewiecki EM.

Ther Clin Risk Manag · review-article; journal article · DOI 10.2147/tcrm.s5645

Bibliografisk träff 2007-05-01

The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene.

Vajdos FF, Hoth LR, Geoghegan KF, Simons SP, LeMotte PK, Danley DE, Ammirati MJ, Pandit J.

Protein Sci · research-article; journal article · DOI 10.1110/ps.062729207

Bibliografisk träff 2005-01-01

Lasofoxifene: CP 336156, CP-336156.

Författaruppgift saknas

Drugs R D · review; journal article · DOI 10.2165/00126839-200506010-00008

Bibliografisk träff 2002-04-01

Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies.

Ke HZ, Brown TA, Thompson DD.

J Am Aging Assoc · research-article; journal article · DOI 10.1007/s11357-002-0007-y

Bibliografisk träff 2001-04-01

Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.

Ke HZ, Qi H, Chidsey-Frink KL, Crawford DT, Thompson DD.

J Bone Miner Res · journal article · DOI 10.1359/jbmr.2001.16.4.765

Bibliografisk träff 2000-12-01

Enzyme-catalyzed asymmetric deacylation for the preparation of lasofoxifene (CP-336156), a selective estrogen receptor modulator.

Yang X, Reinhold AR, Rosati RL, Liu KK.

Org Lett · journal article · DOI 10.1021/ol006652+

Bibliografisk träff 2000-04-01

Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.

Ke HZ, Qi H, Crawford DT, Chidsey-Frink KL, Simmons HA, Thompson DD.

Endocrinology · journal article · DOI 10.1210/endo.141.4.7408

Bibliografisk träff 1999-03-01

CP 336156.

Författaruppgift saknas

Drugs R D · journal article · DOI 10.2165/00126839-199901030-00004

Bibliografisk träff 1998-04-01

Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.

Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WS, Cameron KO, Rosati RL, Brown TA, Dasilva-Jardine P, Thompson DD.

Endocrinology · journal article · DOI 10.1210/endo.139.4.5902